Medpace Voice

As cardiovascular clinical trials evolve, imaging biomarkers have become essential tools for enriching patient populations, evaluating therapeutic response and accelerating...

As biopharmaceutical companies seek to optimize clinical trial design, accelerate regulatory approvals, and improve patient outcomes, insights from JSMO 2025 provide a critical foundation for…

As part of our continuous effort to enhance our laboratory capabilities and better serve our Sponsors, Medpace is proud to announce the expansion of our…

This post is the second of a three-part blog series. In Part 2, we take a look at the biomarkers for chronic kidney disease.

We sat down with Christopher Daniels, Director, Clinical Laboratory Services at Medpace, to discuss regulations and standards for biomarkers, validation process for central labs, and…

As part of our efforts to expand laboratory services and capabilities, Medpace’s central lab in Belgium recently completed extensive expansions including a new modern laboratory…

As more agents approach the clinic, it is imperative for researchers to consider the design and conduct of immuno-oncology clinical trials. Given the diversity of…

Dr. El Mustapha Bahassi, Associate Director of Clinical Laboratories at Medpace, highlights the biomarker landscape in immuno-oncology clinical research.

Medpace Imaging Core Lab has experience and expertise in autoimmune imaging using conventional and molecular imaging methods.

In a recent PharmaVoice article "Brain Wave: Breakthroughs Bring New Hope to CNS", Dr. Rick Scheyer, Vice-President, Medical Affairs at Medpace, provides comment on the state of…